XBIT
XBiotech Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.00
−5.66%Oct 19, 2026, 13:00 UTC
XBiotech Inc. announced final Phase II TASKIN trial results showing 61.3% 12-month overall survival and meeting the prespecified primary efficacy success criterion.
Source: